<DOC>
	<DOCNO>NCT01167309</DOCNO>
	<brief_summary>The purpose trial determine safety tolerability ascend single multiple oral dos LEO 27847 secondary hyperparathyroidism patient .</brief_summary>
	<brief_title>LEO 27847 - Safety , Tolerability , Pharmacokinetic Pharmacodynamic Study Secondary Hyperparathyroidism Patients</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Patients age 18 75 year ( inclusive ) screening . Patients body mass index within 18 34 kg/m2 ( inclusive ) . Haemoglobin stable ( ≥9 g/dL 5.6 mmol/L ) Parathyroid hormone ( PTH ) ≥200 pg/mL &lt; 800 pg/mL . Screening serum albumin ≥30 g/L . Creactive protein &lt; 25 mg/L . Adjustment vitamin D sterols within 14 day screen visit patient adjustment vitamin D sterol plan screen end study . Adjustment calcium supplement within 14 day screen visit patient adjustment calcium supplement plan screen end study . Adjustment phosphate binder within 14 day screen visit patient adjustment phosphate binder plan screen end study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Safety tolerability LEO 27847</keyword>
</DOC>